JP2017538691A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538691A5
JP2017538691A5 JP2017527816A JP2017527816A JP2017538691A5 JP 2017538691 A5 JP2017538691 A5 JP 2017538691A5 JP 2017527816 A JP2017527816 A JP 2017527816A JP 2017527816 A JP2017527816 A JP 2017527816A JP 2017538691 A5 JP2017538691 A5 JP 2017538691A5
Authority
JP
Japan
Prior art keywords
general formula
compound
reaction
xxi
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017527816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538691A (ja
JP6724004B2 (ja
Filing date
Publication date
Priority claimed from GBGB1420594.2A external-priority patent/GB201420594D0/en
Priority claimed from GBGB1420593.4A external-priority patent/GB201420593D0/en
Priority claimed from GBGB1505674.0A external-priority patent/GB201505674D0/en
Application filed filed Critical
Priority claimed from PCT/GB2015/053517 external-priority patent/WO2016079518A1/en
Publication of JP2017538691A publication Critical patent/JP2017538691A/ja
Publication of JP2017538691A5 publication Critical patent/JP2017538691A5/ja
Application granted granted Critical
Publication of JP6724004B2 publication Critical patent/JP6724004B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017527816A 2014-11-19 2015-11-19 ステロイドFXRモジュレーター製造のための中間体としての5β−6−アルキル−7−ヒドロキシ−3−オンステロイド Active JP6724004B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1420594.2A GB201420594D0 (en) 2014-11-19 2014-11-19 Compounds
GB1420594.2 2014-11-19
GBGB1420593.4A GB201420593D0 (en) 2014-11-19 2014-11-19 Compounds
GB1420593.4 2014-11-19
GB1505674.0 2015-04-01
GBGB1505674.0A GB201505674D0 (en) 2015-04-01 2015-04-01 Compounds
PCT/GB2015/053517 WO2016079518A1 (en) 2014-11-19 2015-11-19 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators

Publications (3)

Publication Number Publication Date
JP2017538691A JP2017538691A (ja) 2017-12-28
JP2017538691A5 true JP2017538691A5 (OSRAM) 2019-01-10
JP6724004B2 JP6724004B2 (ja) 2020-07-15

Family

ID=54704020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017527816A Active JP6724004B2 (ja) 2014-11-19 2015-11-19 ステロイドFXRモジュレーター製造のための中間体としての5β−6−アルキル−7−ヒドロキシ−3−オンステロイド

Country Status (14)

Country Link
US (1) US10131688B2 (OSRAM)
EP (1) EP3221332B1 (OSRAM)
JP (1) JP6724004B2 (OSRAM)
KR (1) KR102526632B1 (OSRAM)
CN (1) CN107108687B (OSRAM)
CA (1) CA2968301C (OSRAM)
DK (1) DK3221332T3 (OSRAM)
EA (1) EA033445B1 (OSRAM)
ES (1) ES2733643T3 (OSRAM)
HK (1) HK1244285B (OSRAM)
MX (1) MX375864B (OSRAM)
PL (1) PL3221332T3 (OSRAM)
TW (1) TWI686400B (OSRAM)
WO (1) WO2016079518A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI688571B (zh) 2014-11-19 2020-03-21 英商Nzp英國有限公司 化合物(四)
PL3221331T3 (pl) 2014-11-19 2020-03-31 NZP UK Limited Steroidy, 6-alkilo-7-hydroksy-4-en-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
CA3009149A1 (en) * 2015-12-22 2017-06-29 Intercept Pharmaceuticals, Inc. Polymorphic crystalline forms of obeticholic acid
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
CN106279331B (zh) * 2016-07-27 2019-06-14 宋火良 胆酸类肝病治疗药物
EP3431486A1 (en) 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111138509B (zh) * 2018-11-02 2022-12-06 东莞东阳光药物研发有限公司 奥贝胆酸的制备方法
CN113135970B (zh) * 2020-01-20 2024-11-22 成都贝诺科成生物科技有限公司 一种具有抗芽孢活性的化合物及其药用组合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル リサーチ ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
WO1994019366A1 (en) 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
JP4758608B2 (ja) 2001-11-07 2011-08-31 ネクター セラピューティックス 分枝ポリマーおよびそれらの結合体
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) * 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
EP2040713B1 (en) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
CA2928178C (en) 2007-01-19 2019-09-10 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
EP2324046B1 (en) * 2008-07-30 2014-09-03 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
EP3150620B1 (en) 2008-11-19 2020-01-08 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
NO2698375T3 (OSRAM) 2008-11-19 2018-07-21
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
CA2877122C (en) 2012-06-19 2020-04-28 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
KR102068381B1 (ko) 2012-10-26 2020-01-20 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체의 제조 방법
CA2891348C (en) 2012-11-28 2020-04-28 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
EP2997035B8 (en) 2013-05-14 2018-05-23 Intercept Pharmaceuticals, Inc. 11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
BR112015029318A2 (pt) 2013-05-24 2017-07-25 Nestec Sa marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
EP3149019B1 (en) 2014-05-29 2019-12-04 Bar Pharmaceuticals S.r.l. Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
PL3221331T3 (pl) 2014-11-19 2020-03-31 NZP UK Limited Steroidy, 6-alkilo-7-hydroksy-4-en-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
TWI688571B (zh) 2014-11-19 2020-03-21 英商Nzp英國有限公司 化合物(四)
MX2017006833A (es) 2014-11-26 2018-02-13 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
TW201700447A (zh) 2015-06-19 2017-01-01 英特賽普醫藥品公司 Tgr5調控劑及其用法
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二(叔丁基二甲基硅基氧基)‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技(武汉)有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Similar Documents

Publication Publication Date Title
JP2017538691A5 (OSRAM)
JP2017534669A5 (OSRAM)
JP7426412B2 (ja) カンナビジオール系化合物の製造方法
KR102526631B1 (ko) 스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
KR102527821B1 (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
KR102546748B1 (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
JP2017534670A5 (OSRAM)
KR102526632B1 (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
JP5799171B2 (ja) 1−パルミトイル−3−アセチルグリセロールの製造方法およびこれを利用した1−パルミトイル−2−リノレオイル−3−アセチルグリセロールの製造方法
KR20150018524A (ko) 2-데옥시-2-플루오로-2-메틸-d-리보푸라노실 뉴클레오시드 화합물의 제조 방법
CN103087139B (zh) 一种坎利酮衍生物类甾体化合物、其制备方法及其在制备依普利酮中的用途
JP7116384B2 (ja) 高収率の血管漏出遮断薬の調製方法
CN100447144C (zh) 内酯的立体选择性合成方法
KR20140130425A (ko) 16-치환된-17-케토 스테로이드를 알키닐화하기 위한 공정
CN104781231A (zh) 制备曲伏前列素的方法
US2554473A (en) Process of preparing derivatives of 21-hydroxy-pregnene-(5)-ol-(3)-one-(20)
EP4130020A1 (en) Novel method for preparing inotodiol
KR102436114B1 (ko) 신규한 이노토디올의 제조방법
KR102418153B1 (ko) 신규한 이노토디올의 제조방법
EP1791851B1 (en) Process for preparation of alkyl phosphinates
CN104098642A (zh) 醋酸可的松的中间体、其制备方法以及其在制备醋酸可的松中的用途
JP5143359B2 (ja) ジカルボン酸モノエステルの製造方法
WO2024013382A9 (en) Process for preparing benzoic acid esters and intermediates thereof
CN118027091A (zh) 一种曲前列环素及其中间体的制备方法
WO2022042482A1 (zh) 取代的丙烯酸酯化合物的制备